Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 17 days ago Are T-DXd Results in HER2-Low/Ultralow Breast Cancer Practice-Changing? - 5 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 10 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Dato-DXd More Effective, Tolerable Than Chemo for Metastatic Breast Cancer - 11 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - 12 months ago The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer - about 1 year ago
2	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 21 days ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Another Win for Antibody-Drug Conjugate in HER2+ Breast Cancer With Brain Mets - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - 10 months ago Atezolizumab Plus Carboplatin Boosts Survival in Metastatic TNBC - 11 months ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - 12 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 12 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 2 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 5 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 8 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 9 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 9 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - 11 months ago Datopotamab Deruxtecan Demonstrates Improvement in Progression-Free Survival in HR+, HER2- Breast Cancer - about 1 year ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Breakthrough Therapy Designation to DS-8201a and T-DXd to Treat Metastatic Breast Cancer - 3 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 8 months ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 8 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 8 months ago
7	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	AstraZeneca, Daiichi Sankyo Drug Enhertu Becomes First Tumor-Agnostic ADC Cancer Med - 7 months ago
8	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 9 months ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 10 months ago Abemaciclib, NSAI Extend Overall Survival for Patients With Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer - 10 months ago Tucatinib, Trastuzumab Combination Improves Progression-Free Survival in HER2+, Locally Advanced or Metastatic Breast Cancer - 12 months ago Abemaciclib, Nonsteroidal Aromatase Inhibitor Extends Overall Survival for Patients With HR+, HER2- Advanced Breast Cancer - 12 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 12 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - 12 months ago FDA Approves Zilucoplan for Generalized Myasthenia Gravis in AChR Antibody-Positive Adults - about 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Issues Complete Response Letter to Astellas for Zolbetuximab BLA for GEJ Adenocarcinoma - 10 months ago FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment - 10 months ago ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer - 10 months ago FDA Accepts Biologics License Application for CSL Behring’s Garadacimab for Hereditary Angioedema - 11 months ago

Journalists covering sacituzumab